Shots:

• The P-III PROSPER study involves assessing of Xtandi (160mg- QD) + ADT vs PBO + ADT in 1400 patients with nmCRPC across the US- EU- SA- Canada- and the Asia-Pacific region
• The P-III PROSPER study resulted in meeting its 2EPs i.e. improvement in the OS. In 2018- the study met its 1EPs of MFS- which is included in Xtandi’s label in the US- EU- Japan & is currently under review in China
• Xtandi is an androgen receptor inhibitor- indicated to treat patients with CRPC and mCSPC

Click here ­to­ read full press release/ article | Ref: Pfizer | Image: Equities